Deciphera’s proprietary switch control platform is uniquely capable of producing advanced kinase inhibitors with distinct profiles and qualities for anti-cancer effects. By simultaneously blocking multiple cancer signaling mechanisms, our therapies can control drug-resistant mutations while improving therapeutic potency, durability, and selectivity. With the leading-edge capabilities of our platform and drug development team, we are able to engineer therapies with either kinase-specific or balanced, spectrum-selective profiles to provide greater anti-cancer benefit. Our powerful platform and deep insights have led us to create a portfolio of kinase inhibitors across the spectrum of today’s cancer treatment approaches, including both tumor-targeted therapies and immuno-targeted therapies offering highly-selective immunokinase inhibition.
In many cancers, kinases play a key role in stimulating tumor cells to grow, proliferate, become invasive or hide from the immune system. Deciphera, with its switch control platform, has a proven approach to selectively block kinase activation, even when a tumor has become resistant to other drugs as a result of a mutation. By inhibiting the activity of kinases, we regulate the signaling that promotes cancer growth or protects it from immune cells, for improved anti-cancer effects.
Deciphera’s advanced kinase inhibitors address drug resistance mechanisms to improve rate & durability of responses
Part 1: Kinases direct cell signaling activity to control cellular processes and are regulated by switches to adopt active or inactive kinase states.
Part 2: Deciphera’s switch control inhibitors restore the immune system to a strong cancer fighting state by blocking immunosuppressive kinase activation.